46 completed, 38 recruiting, 25 active not recruiting, 21 terminated. 76 Phase 1, 72 Phase 2, 17 Early Phase 1, 16 Not applicable, 6 Phase 3.
Follow Recurrent Glioblastoma: new trials by email Literature Review of Recurrent Glioblastoma trials Research Report on Recurrent Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 24 | 2027-02-17 | 2026-08-27 |
| OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma CT-179 - Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma | Phase 1 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 54 | 2026-12-01 | 2026-10-28 |
| An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM Device: TheraSphere GBM treatment of TheraSphere GBM device - Recurrent Glioblastoma | Not applicable | Not yet recruiting | Boston Scientific Corporation | 30 | 2026-10-01 | 2026-10-09 |
| Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma SIR-Spheres® - Recurrent Glioblastoma IDH Wildtype, Recurrent Glioblastoma | Early Phase 1 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 12 | 2026-10-01 | 2026-07-17 |
| Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma CHANK-101 - Recurrent Glioblastoma | Not applicable | Not yet recruiting | Dong-A University Hospital | 60 | 2026-09-29 | 2026-09-21 |
| A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma NK Cells - Phase 1, NK Cell | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-08-21 | 2026-08-25 |
| BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma hEGFRvIII-CD3 (BRiTE) - Newly Diagnosed Glioblastoma, Recurrent Glioblastoma | Phase 1 | Recruiting | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 18 | 2026-08-17 | 2026-08-18 |
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma [177Lu]Lu-XT771 - Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma | Early Phase 1 | Recruiting | Beijing Tiantan Hospital | 5 | 2026-06-20 | 2026-06-16 |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma Activated T cells - Recurrent Glioblastoma | Phase 1 | Withdrawn | Jeremy Rudnick, M.D | 2026-06-01 | 2025-10-22 | |
| Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma TGX-007, Valaciclovir - Glioblastoma (GBM), High Grade Gliomas | Phase 1 / Phase 2 | Recruiting | Trogenix ltd | 68 | 2026-04-21 | 2026-10-23 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma Dual-target CAR-NK cells, Cyclophosphamide, Intracranial catheter/reservoir for locoregional delivery - Malignant Glioma, High-Grade Gliomas | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-24 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma Dual-target CAR-NK cells, Cyclophosphamide, Fludarabine - Glioblastoma, High-grade Glioma | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-02-02 | 2026-03-18 |
| A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma Pumitamig, Bevacizumab, Temozolomide - Recurrent Glioblastoma | Phase 2 | Recruiting | BioNTech SE | 75 | 2026-01-15 | 2026-10-28 |
| Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM CART-EGFR-IL13Ra2 T cells - Recurrent Glioblastoma | Phase 1 | Active not recruiting | University of Pennsylvania | 12 | 2025-12-03 | 2026-08-21 |
| Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma Device :DaRT seeds - Recurrent Glioblastoma, Recurrent Gliomas | Not applicable | Recruiting | Alpha Tau Medical LTD. | 10 | 2025-10-01 | 2026-07-21 |
| B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3) - Refractory Glioblastoma, Recurrent Glioblastoma | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 14 | 2025-09-26 | 2025-11-18 |
| A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial Chemotherapy, Computed Tomography, Internet-Based Intervention - Glioma, Recurrent Glioma | Not applicable | Recruiting | Mayo Clinic | 202 | 2025-09-12 | 2026-08-10 |
| Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography - Progressive Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Recruiting | Mayo Clinic | 8 | 2025-08-14 | 2026-08-25 |
Showing 20 of 172. Sign in to see all of them.
Glioblastoma (172) · Glioma (40) · Brain Neoplasms (28) · Gliosarcoma (24) · Astrocytoma (16) · Oligodendroglioma (7) · Recurrence (7) · Neoplasms (4) · Melanoma (3) · Breast Neoplasms (2) · Central Nervous System Neoplasms (2) · Ependymoma (2) · Lymphoma, Follicular (2) · Prostatic Neoplasms (2) · Adenoviridae Infections (1)
Neoplasms, Glandular and Epithelial (172) · Neoplasms, Neuroepithelial (172) · Neuroectodermal Tumors (172) · Neoplasms by Histologic Type (171) · Neoplasms, Germ Cell and Embryonal (171) · Neoplasms, Nerve Tissue (171) · Neoplasms (168) · Astrocytoma (156) · Glioma (132) · Neoplasms by Site (32) · Brain Diseases (30) · Central Nervous System Diseases (30) · Nervous System Diseases (30) · Nervous System Neoplasms (30) · Central Nervous System Neoplasms (28)
Bevacizumab (22) · Temozolomide (19) · Magnetic Resonance Spectroscopy (14) · Specimen Handling (9) · Lomustine (8) · Nivolumab (7) · Radiotherapy (7) · pembrolizumab (7) · Disulfides (6) · Immunoglobulin G (6) · Radiation (6) · Carboplatin (5) · atezolizumab (4) · niraparib (4) · Cyclophosphamide (3)
M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (9) · City of Hope Medical Center (6) · Jonsson Comprehensive Cancer Center (5) · Beijing Tiantan Hospital (4) · Emory University (4) · Mayo Clinic (4) · Northwestern University (4) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · Abramson Cancer Center at Penn Medicine (3) · Dana-Farber Cancer Institute (3) · PharmAbcine (3) · AHS Cancer Control Alberta (2) · AstraZeneca (2) · Beijing Biotech (2)
United States (114) · China (22) · Germany (9) · Australia (7) · Netherlands (7) · Belgium (6) · Canada (6) · South Korea (6) · Switzerland (6) · United Kingdom (5) · Denmark (4) · France (4) · Italy (3) · Spain (3) · Austria (2)
Behnam Badie (3) · Ashley Ghiaseddin, MD (2) · David A Reardon, MD (2) · David Peereboom, MD (2) · Elizabeth Gerstner, MD (2) · Eudocia Q Lee (2) · Jana L Portnow (2) · Jane Robertson (2) · Jasper Gerritsen, MD PhD (2) · Sabine Mueller, MD, PhD (2) · Timothy Cloughesy (2) · Timothy F Cloughesy (2) · Vinay Puduvalli, MD (2) · Abi Vainstein-Haras, MD (1) · Abolhossein Shahverdi, PhD (1)
PMID 21471286, PMID 23940216, PMID 24728273, PMID 25098701, PMID 26643807, PMID 26670466, PMID 28029927, PMID 29943374, PMID 30231931, PMID 30522968, PMID 30771200, PMID 31145289, PMID 31755915, PMID 32034072, PMID 32154928, PMID 32437507, PMID 32619561, PMID 32691060, PMID 33512717, PMID 33744468, PMID 34487222, PMID 34534565, PMID 34824133, PMID 35315341, PMID 35468680, PMID 35552677, PMID 36274161, PMID 36402744, PMID 36549916, PMID 37137304, PMID 37142373, PMID 37590001, PMID 37864646, PMID 38216554, PMID 38454126, PMID 38477966, PMID 38598089, PMID 39105794, PMID 39724015, PMID 39777725, PMID 39970230, PMID 40404984, PMID 41218853, PMID 41276366, PMID 41604000, PMID 41790275, PMID 42229231, PMID 42325608
UM1CA137443 (5), P30CA033572 (4), P30CA138292 (4), P30CA060553 (3), 2023 (2), P30CA015083 (2), P50CA097257 (2), U10CA180821 (2), U10CA180868 (2), P30CA016672 (1), P50CA093459 (1), P50CA108961 (1), P50CA127001 (1), P50CA190991 (1), P50CA211015 (1)